• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

古塞库单抗与阿达木单抗治疗银屑病的疗效比较：随机对照研究的荟萃分析

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies.

作者信息

Fu Hongyi, Guo Jing

机构信息

Department of Medical Cosmetology Center, the first branch of The First Affilliated Hospital of Chongqing Medical University, Chongqing, China.

Department of Dermatology, Youyang People's Hospital, Chongqing, China.

出版信息

Postepy Dermatol Alergol. 2022 Oct;39(5):953-958. doi: 10.5114/ada.2022.120886. Epub 2022 Nov 9.

DOI:10.5114/ada.2022.120886
PMID:36457680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9704462/
Abstract

INTRODUCTION

The efficacy of guselkumab versus adalimumab for psoriasis remains controversial.

AIM

We conducted a systematic review and meta-analysis to explore the influence of guselkumab versus adalimumab on treatment efficacy for psoriasis.

MATERIAL AND METHODS

We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases for randomized controlled trials (RCTs) published until March 2021 and assessing the efficacy and safety of guselkumab versus adalimumab for psoriasis. This meta-analysis was performed using the random-effects model.

RESULTS

Three RCTs were included in the meta-analysis. Overall, compared with adalimumab for psoriasis, guselkumab was associated with improved PASI 100 (OR = 2.18; 95% CI: 1.47 to 3.23; = 0.0001), PASI 90 (OR = 2.63; 95% CI: 2.11 to 3.27; < 0.00001), PASI 75 (OR = 3.10; 95% CI: 2.35 to 4.08; < 0.00001) and PGA 0/1 (OR = 2.04; 95% CI: 1.26 to 3.31; = 0.004), as well as decreased DLQI (SMD = -0.24; 95% CI: -0.34 to -0.13; < 0.00001). In addition, guselkumab resulted in higher DLQI score 0/1 (OR = 1.88; 95% CI: 1.51 to 2.33; < 0.00001) than adalimumab.

CONCLUSIONS

Guselkumab showed better efficacy than adalimumab for psoriasis.

摘要

引言

古塞库单抗与阿达木单抗治疗银屑病的疗效仍存在争议。

目的

我们进行了一项系统评价和荟萃分析，以探讨古塞库单抗与阿达木单抗对银屑病治疗疗效的影响。

材料与方法

我们检索了PubMed、Embase、Web of Science、EBSCO和Cochrane图书馆数据库，查找截至2021年3月发表的随机对照试验（RCT），评估古塞库单抗与阿达木单抗治疗银屑病的疗效和安全性。本荟萃分析采用随机效应模型。

结果

三项RCT纳入了荟萃分析。总体而言,与阿达木单抗治疗银屑病相比，古塞库单抗与达到PASI 100改善（OR = 2.18；95% CI：1.47至3.23；P = 0.0001）、PASI 90改善（OR = 2.63；95% CI：2.11至3.27；P < 0.00001）、PASI 75改善（OR = 3.10；95% CI：2.35至4.08；P < 0.00001）以及PGA 0/1改善（OR = 2.04；95% CI：1.26至3.31；P = 0.004）相关，同时与较低的DLQI（SMD = -0.24；95% CI：-0.34至-0.13；P < 0.00001）相关。此外，与阿达木单抗相比，古塞库单抗导致更高的DLQI评分0/1（OR = 1.88；95% CI：1.51至2.33；P < 0.00001）。

结论

对于银屑病，古塞库单抗显示出比阿达木单抗更好的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/3151e568d178/PDIA-39-48125-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/b6335753eeb9/PDIA-39-48125-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/0f7a4d6e360d/PDIA-39-48125-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/1c921599e5d9/PDIA-39-48125-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/f09d9a150ed9/PDIA-39-48125-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/1edd7ca15fde/PDIA-39-48125-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/9a252a38819d/PDIA-39-48125-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/3151e568d178/PDIA-39-48125-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/b6335753eeb9/PDIA-39-48125-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/0f7a4d6e360d/PDIA-39-48125-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/1c921599e5d9/PDIA-39-48125-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/f09d9a150ed9/PDIA-39-48125-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/1edd7ca15fde/PDIA-39-48125-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/9a252a38819d/PDIA-39-48125-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe4/9704462/3151e568d178/PDIA-39-48125-g007.jpg

相似文献

1
Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies.古塞库单抗与阿达木单抗治疗银屑病的疗效比较：随机对照研究的荟萃分析
Postepy Dermatol Alergol. 2022 Oct;39(5):953-958. doi: 10.5114/ada.2022.120886. Epub 2022 Nov 9.
2
Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.评估 Guselkumab 治疗中重度斑块状银屑病的短期疗效和安全性：随机对照试验的荟萃分析。
J Immunol Res. 2020 Jul 17;2020:4975628. doi: 10.1155/2020/4975628. eCollection 2020.
3
Comparison of adalimumab with methotrexate for psoriasis: A meta-analysis of randomized controlled studies.阿达木单抗与甲氨蝶呤治疗银屑病的比较：一项随机对照研究的荟萃分析。
Medicine (Baltimore). 2024 Aug 9;103(32):e37216. doi: 10.1097/MD.0000000000037216.
4
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
5
Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies.阿普米司特治疗银屑病的疗效：随机对照研究的荟萃分析。
Postepy Dermatol Alergol. 2023 Feb;40(1):165-170. doi: 10.5114/ada.2022.119081. Epub 2022 Sep 6.
6
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.古塞单抗治疗特定身体区域银屑病的疗效与阿达木单抗和安慰剂的比较：两项随机临床试验的二次分析。
JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793.
7
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.银屑病患者使用古塞库单抗治疗的一致性应答：来自 VOYAGE 1 和 VOYAGE 2 的分析。
J Dermatolog Treat. 2021 Aug;32(5):484-491. doi: 10.1080/09546634.2019.1679336. Epub 2019 Oct 21.
8
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
9
Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.在中度至重度银屑病韩国患者中，古塞库单抗与安慰剂和阿达木单抗相比的疗效和安全性：来自 III 期、双盲、安慰剂和阳性对照对照 VOYAGE 1/2 试验的分析。
J Dermatolog Treat. 2022 Feb;33(1):535-541. doi: 10.1080/09546634.2020.1770174. Epub 2020 May 27.
10
Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.使用头对头试验中度至重度斑块型银屑病的数据，比较古塞单抗与阿达木单抗在美国的每反应成本。
J Med Econ. 2019 Dec;22(12):1268-1273. doi: 10.1080/13696998.2019.1632204. Epub 2019 Jul 1.

引用本文的文献

1
Predictors of PASI90 response in patients with psoriasis treated with ınterleukin ınhibitors: observational cohort study.接受白细胞介素抑制剂治疗的银屑病患者达到PASI90缓解的预测因素：观察性队列研究。
An Bras Dermatol. 2025 Jun 18;100(4):501132. doi: 10.1016/j.abd.2025.501132.
2
Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial.抗白细胞介素-23单克隆抗体QX004N用于银屑病患者的安全性和有效性：一项随机临床试验
JAMA Dermatol. 2025 Mar 1;161(3):247-255. doi: 10.1001/jamadermatol.2024.5059.
3
Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis.

本文引用的文献

1
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.银屑病的病理生理学、临床表现和治疗：综述。
JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006.
2
Adalimumab-induced scalp psoriasis with severe alopecia.阿达木单抗诱导的头皮银屑病伴严重脱发。
Dermatol Ther. 2019 Sep;32(5):e13033. doi: 10.1111/dth.13033. Epub 2019 Aug 22.
3
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.阿达木单抗治疗甲银屑病：来自一项 3 期、随机、安慰剂对照试验的 52 周疗效和安全性。
基因本体分析突出了影响银屑病生物治疗反应性的生物学过程。
Pharmaceutics. 2023 Jul 26;15(8):2024. doi: 10.3390/pharmaceutics15082024.
4
Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis.在中度至重度斑块状银屑病系统治疗的有效性和耐受性评估中，将Meta分析与ChatGPT进行比较。
J Clin Med. 2023 Aug 20;12(16):5410. doi: 10.3390/jcm12165410.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药物治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6.
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2168-2178. doi: 10.1111/jdv.15793. Epub 2019 Sep 4.
4
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.阿达木单抗治疗甲银屑病：3 期随机安慰剂对照试验前 26 周的疗效和安全性。
J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1. doi: 10.1016/j.jaad.2017.08.029. Epub 2017 Oct 6.
5
Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide.阿达木单抗治疗慢性斑块状银屑病：临床指南。
J Drugs Dermatol. 2017 Aug 1;16(8):779-790.
6
Diagnosis and management of psoriasis.银屑病的诊断与管理
Can Fam Physician. 2017 Apr;63(4):278-285.
7
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
8
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
9
Psoriasis.银屑病。
Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82.
10
Clinical meaningfulness of complete skin clearance in psoriasis.银屑病完全皮肤清除的临床意义。
J Am Acad Dermatol. 2016 Jul;75(1):77-82.e7. doi: 10.1016/j.jaad.2016.03.026. Epub 2016 May 17.